

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 December 2005 (08.12.2005)

PCT

(10) International Publication Number
WO 2005/115369 A3

(51) International Patent Classification:

A61K 31/192 (2006.01) A61P 15/00 (2006.01)
A61K 31/451 (2006.01) A61P 37/00 (2006.01)
A61P 1/00 (2006.01) A23K 1/16 (2006.01)
A61P 1/16 (2006.01) A23K 1/18 (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:

PCT/IB2005/001501

(22) International Filing Date: 13 May 2005 (13.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/574,136 25 May 2004 (25.05.2004) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOETZE, Leopold, Franz** [DE/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT19 9NJ (GB). **KEHRLI, Marcus, Eugene, Jr** [US/US]; Pfizer Global Research and Development, European Pharma Patents Department, Ramsgate Road, Sandwich, Kent CT19 9NJ (GB). **RICKETTS, Anthony, Paul** [GB/US]; Pfizer Inc., Eastern Point Road, Groton, CT 06340 (US). **TAUBE, Patrick, Carl** [US/US]; Pfizer Inc., 5300 North 28th Street, Richland, Michigan 49083 (US).

(74) Agents: **WOOD, David, J.** et al.; Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

16 November 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF PPAR AGONISTS TO TREAT RUMINANTS

(57) Abstract: The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentrations, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-) -metritis, infertility, low fertility, lameness, subacute rumen acidosis and inadequate nutrient intake associated with stress e.g. heat, poor housing, overcrowding, shipping, dominance or illness, and to increase milk quality and yield.



WO 2005/115369 A3